Skip to main content
SpringerLink
Log in

Interdisciplinary Approach in Breast Cancer

  • Chapter
  • First Online:
Interdisciplinary Cancer Research

Part of the book series: Interdisciplinary Cancer Research

Abstract

Breast cancer (BC) is a highly heterogeneous disease with different underlying genetic alterations and various patient manifestations. The disease management approach is going through a remarkable change from a one-size-fits-all setting to tailored therapy. Effective screening, early diagnosis, molecular profiling, new surgical techniques, and radiation therapies significantly improve BC management. This collaborative multidisciplinary approach through harmonizing and synthesizing links between symptoms and signs could elaborate the most effective therapeutic strategy at the best time! This chapter provides an overview of different areas of tailored therapy in BC patients with an interdisciplinary perspective. The following chapters of this volume will focus on more details of current therapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Darbeheshti F, Izadi P, Razavi ANE, Kamali F, Yekaninejad MS, Bazzaz JT (2018) Significance of EGFR mRNA expression in luminal and triple negative breast tumors. Int J Cancer Manag 11:e9763

    Google Scholar 

  • Darbeheshti F, Rezaei N, Amoli MM, Mansoori Y, Bazzaz JT (2019) Integrative analyses of triple negative dysregulated transcripts compared with non-triple negative tumors and their functional and molecular interactions. J Cell Physiol 234:22386–22399

    Google Scholar 

  • Darbeheshti F, Mahdiannasser M, Noroozi Z, Firoozi Z, Mansoori B, Daraei A, Bastami M, Nariman-Saleh-Fam Z, Valipour E, Mansoori Y (2021a) Circular RNA-associated ceRNA network involved in HIF-1 signalling in triple-negative breast cancer: circ_0047303 as a potential key regulator. J Cell Mol Med 25:11322–11332

    Google Scholar 

  • Darbeheshti F, Zokaei E, Mansoori Y, Allahyari SE, Kamaliyan Z, Kadkhoda S, Bazzaz JT, Rezaei N, Shakoori A (2021b) Circular RNA hsa_circ_0044234 as distinct molecular signature of triple negative breast cancer: a potential regulator of GATA3. Cancer Cell Int 21:1–12

    Google Scholar 

  • Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816

    Google Scholar 

  • De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. In: Database of abstracts of reviews of effects (DARE): quality-assessed reviews [internet]. Centre for Reviews and Dissemination, York

    Google Scholar 

  • Gilbo P, Potters L, Lee L (2018) Implementation and utilization of hypofractionation for breast cancer. Adv Radiat Oncol 3:265–270

    Google Scholar 

  • Guo R, Guolan L, Qin B, Fei B (2018) Ultrasound imaging technologies for breast cancer detection and management: a review. Ultrasound Med Biol 44:37–70

    Google Scholar 

  • Gydush G, Nguyen E, Bae JH, Rhoades J, Reed SC, Shea D, Xiong K, Liu R, Blewett T, Yu F (2021) MAESTRO affords ‘breadth and depth’ for mutation testing. bioRxiv. https://doi.org/10.1101/2021.01.22.427323

  • Gydush G, Nguyen E, Bae JH, Blewett T, Rhoades J, Reed SC, Shea D, Xiong K, Liu R, Yu F (2022) Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth. Nat Biomed Eng 6:1–10

    Google Scholar 

  • Haley B, Batra K, Sahoo S, Froehlich T, Klemow D, Unni N, Ahn C, Rodriguez M, Hullings M, Frankel AE (2021) A phase I/Ib trial of PD 0332991 (palbociclib) and T-DM1 in HER2-positive advanced breast cancer after trastuzumab and taxane therapy. Clin Breast Cancer 21:417–424

    Google Scholar 

  • Haviland JS, A’Hern R, Bentzen SM, Whelan T, Bliss JM (2014) Radiotherapy for breast cancer, the TARGIT-A trial. Lancet 383:1716–1717

    Google Scholar 

  • Herzog SK, Fuqua SAW (2021) ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer 126:1–13

    Google Scholar 

  • Honrado E, Benítez J, Palacios J (2005) The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 18:1305–1320

    Google Scholar 

  • Imyanitov EN (2021) Cytotoxic and targeted therapy for BRCA1/2-driven cancers. Hered Cancer Clin Pract 19:1–8

    Google Scholar 

  • İzci F, İlgün AS, Fındıklı E, Özmen V (2016) Psychiatric symptoms and psychosocial problems in patients with breast cancer. J Breast Health 12:94

    Google Scholar 

  • Jalalvand M, Darbeheshti F, Rezaei N (2021) Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer. Immunotherapy 13:587–603

    Google Scholar 

  • June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359:1361–1365

    Google Scholar 

  • Kashyap D, Kaur H (2020) Cell-free miRNAs as non-invasive biomarkers in breast cancer: significance in early diagnosis and metastasis prediction. Life Sci 246:117417

    Google Scholar 

  • Kotake M, Imai H, Kaira K, Fujisawa T, Yanagita Y, Minato K (2019) Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study. Cancer Chemother Pharmacol 84:655–660

    Google Scholar 

  • Leong KW, Yu F, Mike Makrigiorgos G (2021) Mutation enrichment in human DNA samples via UV-mediated cross-linking. Nucleic Acids Res 50:e32

    Google Scholar 

  • Liang X, Li H, Coussy F, Callens C, Lerebours F (2019) An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: do we make progress? Chin J Cancer Res 31:586

    Google Scholar 

  • Ma W, Sun J, Jieni X, Luo Z, Diao D, Zhang Z, Oberly PJ, Minnigh MB, Xie W, Poloyac SM (2020) Sensitizing triple negative breast cancer to tamoxifen chemotherapy via a redox-responsive vorinostat-containing polymeric prodrug nanocarrier. Theranostics 10:2463

    Google Scholar 

  • Maennling AE, Tur MK, Niebert M, Klockenbring T, Zeppernick F, Gattenlöhner S, Meinhold-Heerlein I, Hussain AF (2019) Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials. Cancers 11:1826

    Google Scholar 

  • Mann RM, Kuhl CK, Moy L (2019) Contrast-enhanced MRI for breast cancer screening. J Magn Reson Imaging 50:377–390

    Google Scholar 

  • Martin JM, Goldstein LJ (2018) Profile of abemaciclib and its potential in the treatment of breast cancer. Onco Targets Ther 11:5253

    Google Scholar 

  • Mavratzas A, Marmé F (2021) Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations. Future Oncol 17:13–36

    Google Scholar 

  • Mazumder A, Shiao S, Haricharan S (2021) HER2 activation and endocrine treatment resistance in HER2-negative breast cancer. Endocrinology 162:bqab153

    Google Scholar 

  • McCann KE (2019) Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib. Future Oncol 15:1707–1715

    Google Scholar 

  • Montero A, Ciervide R, Garcia-Aranda M, Rubio C (2020) Postmastectomy radiation therapy in early breast cancer: utility or futility? Crit Rev Oncol Hematol 147:102887

    Google Scholar 

  • Murugappan K, Saboo A, Kuo L, Ung O (2018) Paradigm shift in the local treatment of breast cancer: mastectomy to breast conservation surgery. Gland Surg 7:506

    Google Scholar 

  • O’Shaughnessy J, Thaddeus Beck J, Royce M (2018) Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer. Cancer Treat Rev 69:204–214

    Google Scholar 

  • Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, Xiong K, Lo CC, Li T, Fleharty M (2020) Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clin Cancer Res 26:2556–2564

    Google Scholar 

  • Peng X, Sun Z, Kuang P, Chen J (2020) Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. Eur J Med Chem 208:112831

    Google Scholar 

  • Qaseem A, Lin JS, Mustafa RA, Horwitch CA, Wilt TJ (2019) Screening for breast cancer in average-risk women: a guidance statement from the American College of Physicians. Ann Intern Med 170:547–560

    Google Scholar 

  • Raj VS, Pugh TM, Yaguda SI, Mitchell CH, Mullan SS, Garces NS (2020) The who, what, why, when, where, and how of team-based interdisciplinary cancer rehabilitation. Semin Oncol Nurs 36:150974. Elsevier

    Google Scholar 

  • Renke J, Wasilewska E, Kędzierska-Mieszkowska S, Zorena K, Barańska S, Wenta T, Liberek A, Siluk D, Żurawa-Janicka D, Szczepankiewicz A, Renke M, Lipińska B (2020) Tumor suppressors-HTRA proteases and Interleukin-12-in pediatric asthma and allergic rhinitis patients. Medicina (Kaunas) 56:298

    Google Scholar 

  • Riedel F, Hoffmann AS, Moderow M, Heublein S, Deutsch TM, Golatta M, Wallwiener M, Schneeweiss A, Heil J, Hennigs A (2020) Time trends of neoadjuvant chemotherapy for early breast cancer. Int J Cancer 147:3049–3058

    Google Scholar 

  • Shen L, Margolies LR, Rothstein JH, Fluder E, McBride R, Sieh W (2019) Deep learning to improve breast cancer detection on screening mammography. Sci Rep 9:1–12

    Google Scholar 

  • Sun H, Wenwen H, Yan Y, Zhang Z, Chen Y, Yao X, Teng L, Wang X, Chai D, Zheng J (2021) Using PAMPs and DAMPs as adjuvants in cancer vaccines. Hum Vaccin Immunother 17:1–12

    Google Scholar 

  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249

    Google Scholar 

  • Szymiczek A, Lone A, Akbari MR (2021) Molecular intrinsic versus clinical subtyping in breast cancer: a comprehensive review. Clin Genet 99:613–637

    Google Scholar 

  • Tadros AB, Sevilimedu V, Giri DD, Zabor EC, Morrow M, Plitas G (2021) Survival outcomes for metaplastic breast cancer differ by histologic subtype. Ann Surg Oncol 28:1–9

    Google Scholar 

  • Vlastos G, Verkooijen HM (2007) Minimally invasive approaches for diagnosis and treatment of early-stage breast cancer. Oncologist 12:1–10

    Google Scholar 

  • Xin L, Liu Y-H, Martin TA, Jiang WG (2017) The era of multigene panels comes? The clinical utility of Oncotype DX and Mammaprint. World J Oncol 8:34

    Google Scholar 

  • Xuhong J-C, Qi X-W, Zhang Y, Jiang J (2019) Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Cancer Res 9:2103

    Google Scholar 

  • Zokaei E, Darbeheshti F, Rezaei N (2022) Prospect of exosomal circular RNAs in breast Cancer: presents and future. Mol Biol Rep 9:1–5

    Google Scholar 

  • Zollo M, Di Dato V, Spano D, De Martino D, Liguori L, Marino N, Vastolo V, Navas L, Garrone B, Mangano G (2012) Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin Exp Metastasis 29:585–601

    Google Scholar 

Download references

Acknowledgments

None.

Author information

Authors and Affiliations

  1. Department of Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Farzaneh Darbeheshti

  2. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran

    Farzaneh Darbeheshti

  3. Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran

    Nima Rezaei

  4. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Nima Rezaei

  5. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Stockholm, Sweden

    Nima Rezaei

Authors
  1. Farzaneh Darbeheshti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nima Rezaei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nima Rezaei .

Ethics declarations

The authors declare that there is no conflict of interest.

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Darbeheshti, F., Rezaei, N. (2022). Interdisciplinary Approach in Breast Cancer. In: Interdisciplinary Cancer Research. Springer, Cham. https://doi.org/10.1007/16833_2022_10

Download citation

  • DOI: https://doi.org/10.1007/16833_2022_10

  • Published:

  • Publisher Name: Springer, Cham

Publish with us

Policies and ethics

Search

Navigation